Хайлтын үр дүнгүүд - M. Albulescu

  • 5-н 1 - 5 үр дүнгүүдийг харуулж байна
Үр дүнг сайжруулах
  1. 1
    Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials

    Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials -н Ian N Bruce, Richard Furie, Eric F. Morand, Susan Manzi, Yoshiya Tanaka, Kenneth Kalunian, Joan T. Merrill, Patricia Puzio, Emmanuelle Maho, C. Kleoudis, M. Albulescu, Micki Hultquist, Raj Tummala

    Хэвлэсэн 2022
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  2. 2
    Mavrilimumab, a Fully Human Granulocyte–Macrophage Colony‐Stimulating Factor Receptor α Monoclonal Antibody

    Mavrilimumab, a Fully Human Granulocyte–Macrophage Colony‐Stimulating Factor Receptor α Monoclonal Antibody -н Gerd R Burmester, Iain B. McInnes, Joel M. Kremer, Pedro C. Miranda, Jiří Vencovský, A. Godwood, M. Albulescu, M. Alex Michaels, Xiang Guo, D. Close, Michael E. Weinblatt

    Хэвлэсэн 2018
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  3. 3
    A Randomized Phase <scp>II</scp>b Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis

    A Randomized Phase <scp>II</scp>b Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis -н Michael E. Weinblatt, Iain B. McInnes, Joel M. Kremer, Pedro C. Miranda, Jiří Vencovský, Xiang Guo, Wendy I. White, Patricia C. Ryan, A. Godwood, M. Albulescu, D. Close, Gerd R Burmester

    Хэвлэсэн 2017
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  4. 4
    A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationale

    A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic scl... -н Dinesh Khanna, Christopher P. Denton, Shervin Assassi, Masataka Kuwana, Yannick Allanore, Robyn T. Domsic, C. Kleoudis, John Xu, Eszter Csomor, Caroline Seo, M. Albulescu, Raj Tummala, Hussein Al‐Mossawi, Rubana N. Kalyani, Francesco Del Galdo

    Хэвлэсэн 2024
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  5. 5
    A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity

    A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity -н Jodi L. Karnell, M. Albulescu, Stacey Drabic, Xue Wang, Rachel Moate, Manuel Baca, Vaheh Oganesyan, Michele Gunsior, Thomas Thisted, Yan Li, Jing Li, Ximing Xiong, Steven Eck, Melissa de los Reyes, Isharat Yusuf, Katie Streicher, Ulf Müller‐Ladner, David Howe, Rachel Ettinger, Ronald Herbst, Jörn Drappa

    Хэвлэсэн 2019
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:

Хайх хэрэгслүүд: